SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
February 7, 2003
Date of Report (Date of Earliest Event Reported)
(Exact name of registrant as specified in its charter)
|
(State or other jurisdiction |
(Commission File Number) |
(IRS Employer |
|
(Address of principal executive offices, including Zip Code) |
|
|
(908) 298-4000 |
|
Item 5. Other Events and Regulation FD Disclosure
Schering-Plough today issued a press release titled "Schering-Plough In Licensing Agreement With Three Rivers Pharmaceuticals Resolving U.S. Ribavirin Patent Dispute." The press release is attached to this 8-K as Exhibit 99.1.
Item 7. Financial Statements and Exhibits
(c) Exhibits. The following exhibits are filed with this 8-K:
99.1 Press Release Dated February 7, 2003 Titled "Schering-Plough In Licensing Agreement With Three Rivers Pharmaceuticals Resolving U.S. Ribavirin Patent Dispute"
99.2 Q&A On Three Rivers Ribavirin Patent Agreement
Item 9. Regulation FD Disclosure
Schering-Plough expects to receive and answer questions from investors and the media about the matters reported in the press release. Attached as Exhibit 99.2 is a list of anticipated questions and answers.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Schering-Plough Corporation
By: /s/ Thomas H. Kelly
Thomas H. Kelly
Vice President and Controller
Date: February 7, 2003
Exhibit Index
The following exhibits are filed with this 8-K:
99.1 Press Release Dated February 7, 2003 Titled "Schering-Plough In
Licensing Agreement With Three Rivers Pharmaceuticals Resolving U.S. Ribavirin Patent Dispute"99.2
Q&A On Three Rivers Ribavirin Patent Agreement